Raltegravir functions as a potent HIV integrase strand transfer inhibitor for infection management. By blocking the integration of viral DNA into host chromosomes, this antiviral agent successfully arrests the replication cycle of the virus.
Raltegravir belongs to a class of medicines known as integrase strand-transfer inhibitors. It works by interfering with a step that the HIV virus needs to insert its genetic material into human cells. Because of this action, Raltegravir is used as part of combination therapy for people living with HIV. The compound appears in several formulations, most notably the brand-named product Isentress, which is marketed in Singapore.
In Singapore, Raltegravir is supplied primarily as the tablet form found in Isentress. Generic versions may also be available, offering the same active ingredient in identical strength. The tablets are taken orally and are packaged in blister packs or bottles, following the standard labeling practices of the Health Sciences Authority (HSA). While the active substance remains consistent, the excipients and tablet size can vary between brands.
These applications reflect why Raltegravir medications are included in many standard HIV treatment plans across the region.
When taken, Raltegravir enters the bloodstream and reaches cells that harbour HIV. It blocks the viral enzyme called integrase, which the virus requires to splice its DNA into the host’s genetic material. By stopping this step, the drug reduces the ability of the virus to reproduce, allowing the immune system to recover over time. The effect is measured through viral load tests rather than immediate symptom relief.
These symptoms are generally short-lived and may lessen as the body adjusts.
If any of these appear, medical attention should be sought promptly.
People with known hypersensitivity to Raltegravir or any ingredient in the tablet should avoid it. Pregnant individuals are advised to discuss use with a healthcare professional, as are those with severe liver impairment.
Raltegravir may interact with certain drugs that affect liver enzymes, including some antiepileptics and rifampicin-based treatments. Alcohol consumption can increase the feeling of nausea. Detailed interaction tables are provided on the specific medication’s information sheet.
For detailed usage, dosing, and administration, refer to the specific medication’s clinical information.
This article provides an educational overview of Raltegravir as an active substance and does not constitute medical advice. Individual medicines that contain this component, such as Isentress, may differ in formulation, strength, and instructions. The information is offered without liability for clinical application. Readers are encouraged to review the labeling of their specific medicine and seek guidance from a qualified healthcare professional when needed.
